Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry · 13.06.2024 · 67 (11) · 9628-9644
DOI: 10.1021/acs.jmedchem.4c00788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.05.2024. Verfasst von Mengyao Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Multiple Sclerosis, Phosphoinositide-3 Kinase Inhibitors, Encephalomyelitis, Autoimmune, Experimental, Class I Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Program for Support of Top-notch Young Professionals, Key Research and Development Program of Zhejiang Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system and the unmet need for MS treatment demands new therapeutic development. Particularly, PI3Kδ is a high-value target for autoimmune disease, while the investigation of PI3Kδ inhibitors for MS therapy is relatively scarce. Herein, we report a novel class of azaindoles as PI3Kδ inhibitors for MS treatment. Compound 31, designed via nitrogen bioisosterism, displayed excellent PI3Kδ inhibitory activity and selectivity. In vitro assay showed that 31 exhibited superior activity on T lymphocytes to inhibit the proliferation of CD4+, CD8+, and CD3+ T cells. In the experimental autoimmune encephalomyelitis (EAE) model, 31 showed a comparable therapeutical efficacy with Dexamethasone to significantly ameliorate EAE symptoms. Mechanistic studies showed that compound 31 could significantly inhibit the PI3K/AKT/mTOR signaling pathway and inhibited T-cell proliferation and differentiation. Overall, this work provides a new structural PI3Kδ inhibitor and a new vision for MS therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China.
- Taizhou Institute of Zhejiang University, Taizhou 318000, China.
ORCID-Profile: Sunliang Cui
Förderung
- National Program for Support of Top-notch Young Professionals
- Key Research and Development Program of Zhejiang Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Zhejiang Provincial Outstanding Youth Science Foundation
Zitieren
APA
Yu, M., Wang, X., Tang, Y., Wang, L., Hu, X., Weng, Q., Wang, J., & Cui, S. (2024). Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry, 67(11), 9628-9644. https://doi.org/10.1021/acs.jmedchem.4c00788
Vancouver
Yu M, Wang X, Tang Y, Wang L, Hu X, Weng Q, et al. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry. 2024;67(11):9628-9644. doi:10.1021/acs.jmedchem.4c00788
BibTeX
@article{Yu2024,
author = {Yu, Mengyao and Wang, Xian and Tang, Yongmei and Wang, Longling and Hu, Xueping and Weng, Qinjie and Wang, Jiajia and Cui, Sunliang},
title = {Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {11},
pages = {9628--9644},
doi = {10.1021/acs.jmedchem.4c00788}
}
EUVIMED